# **Evusheld Referral Form**



#### **Patient Information**

Last Name	First Name		DOB		
Gender	Social Security #		Primary Language		
Address					
City		State	ZIP		
Allergies					
Phone	Height		Weight		
ICD-10 Code Code Qualifying diagnosis U09.9 Post COVID-19 condition unspecified					

## Prescriber Information

Name of Contact Sending Referral	Title			
Preferred Email Contact Method Phone (check one) Fax	Referral Contact Email			
Office Phone	Office Fax			
Practice/Facility Name				
Address				
City	State	ZIP		
Prescriber Name/Specialty				

# Insurance Information Insurance Provider Plan ID # Eligible for Medicare (check one) Yes No List Red, White & Blue Card # Insured's Name Relationship to Patient If no insurance, list driver's license number and state of issue

#### Please fax with order form: Current Medication List & Copy of Insurance Card

### Eligibility

Exclusion Criteria: EVUSHELD is not authorized for use in individuals:

- For treatment of COVID-19.
- For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2.
   Pre-exposure prophylaxis with EVUSHELD is not a substitute for vaccination
- Pre-exposure prophylaxis with EVUSHELD is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate to severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID-19 vaccination.
- In individuals who have received a COVID-19 vaccine, EVUSHELD should be administered at least two weeks after vaccination.

#### Inclusion Criteria: Check all that apply

For the pre-exposure prophylaxis of COVID-19 in adults and pediatric individuals (12 years of age and older weighing at least 40 kg).

Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARSCoV-2 and:

Who have moderate to severe immune compromise due to a medical condition such as cancer, untreated HIV, etc. (not a complete list, see EUA for more).

Who receive immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination.

#### **Medication Orders**

\*EVUSHELD may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs in the therapeutic class to which EVUSHELD belongs (i.e., anti-infectives). Standing orders may not be used per the EUA.

\*EVUSHELD New One Time Dose: EVUSHELD once 300mg tixagevimab IM and 300mg cilgavimab IM as separate IM injections.

\*EVUSHELD Previous 150 mg/150 mg Dose: Additional EVUSHELD one time 150 mg tixagevimab IM and 150 mg cilgavimab IM as separate IM injections. If patient has received 150 mg equal to or less than 90 days previously they should receive an additional 150 mg/150 mg dose.

Anaphylaxis Kit per Hy-Vee Health anaphylaxis treatment protocol.

#### Indicate vaccination status:

Unvaccinated Partially Vaccinated Fully Vaccinated Boosted

#### **Nursing Orders**

Administer IM in two injections, monitor patient for one hour post injection, follow anaphylaxis treatment protocol if necessary.

Phone: 515.225.2930 Fax: 515.559.2495 Prescriber Signature

Date

NPI